ClinicalTrials.gg
CompletedNCT00658632Updated May 4, 2016Results posted

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

A Phase 3 interventional study of Rabeprazole sodium and Esomeprazole in Gastroesophageal Reflux Disease (GERD), sponsored by Eisai Inc.. Completed at 85 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-05-04.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,397
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing rabeprazole in Gastroesophageal Reflux — none open to participants now, none under way, none of them phase 3. Rabeprazole · Gastroesophageal Reflux.

Enrollment
Largest of 39
1,397 · median 100
Started
2008
with 7 others
Phase 3
16 of 40
none open now
Registered
19th of 40
by date
Lead sponsor
9 of 40
Eisai Inc.

Among the 40 studies testing rabeprazole in Gastroesophageal Reflux, this one has the largest enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2008, is one of 16 in phase 3, and was the 19th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

None of the 40 studies testing rabeprazole in Gastroesophageal Reflux is open now. The open studies under Gastroesophageal Reflux, anywhere →

About rabeprazole

Rabeprazole: first FDA approval 1999 (ACIPHEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing rabeprazole in Gastroesophageal Reflux as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).

Read the detailed description

This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of mild to moderate erosive Gastroesophageal Reflux Disease (GERD).

03

Conditions studied

  • Gastroesophageal Reflux Disease (GERD)

Keywords

  • GERD
  • erosive GERD
  • erosive esophagitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY INCLUSION CRITERIA:

  1. Male or female, ages 18 to 75 years.
  2. History of gastroesophageal reflux disease (GERD) symptoms for at least 3 months immediately before screening.
  3. Heartburn for at least 2 days a week for at least 1 month before screening.
  4. Esophageal erosions of Los Angeles (LA) Grades A or B based on EGD taken within 14 days prior to enrollment.
  5. Subjects who are H. pylori negative based on a screening test.
  6. Females should be either of non- or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of .
  7. Subjects must be able to read, write, and understand the language of the symptom diary.

KEY EXCLUSION CRITERIA:

  1. Current or a history of esophageal motility disorders.
  2. Current or a history of Barrett's esophagus. Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
  3. Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
  4. Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
  5. Inflammatory bowel disease.
  6. Unstable diabetes mellitus.
  7. History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.
  8. Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral (>=20 mg/day prednisone or equivalent), or aspirin (> 325 mg/day).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,397 participants (actual)

Study arms

  • Experimental
    1

    Drug: Rabeprazole sodium

  • Active comparator
    2

    Drug: Esomeprazole

Interventions

  • Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.

    Also known as: Aciphex

  • Esomeprazole 40 mg capsule, once daily for 4-8 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

    Healing at Week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade A or B from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Gread D: Mucosal breaks involving at least 75% of the esophageal circumference.

    Time frame: Baseline and Week 8

  2. Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

    Healing at Week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade A or B from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Gread D: Mucosal breaks involving at least 75% of the esophageal circumference.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

    During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.

    Time frame: Week 4

07

Results

Posted Jun 23, 2015

Participant flow

Participant flow — Overall Study
MilestoneEsomeprazole (ESO) 40 mgRabeprazole (RAB) Extended Release (ER) 50 mg
Started682698
Completed618633
Not completed6465
Withdrew: Adverse event1311
Withdrew: Lost to follow-up2523
Withdrew: Withdrawal by subject107
Withdrew: Lack of efficacy01
Withdrew: Withdrawal of consent814
Withdrew: Pregnancy11
Withdrew: Other78

Outcome measures

SecondaryPercentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4

During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.

Time frame:
Week 4
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
Percentage of ParticipantsESO 40 mgRAB ER 50 mg
Yes38.541.9
No50.847.1
Missing10.711
PrimaryPercentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks

Healing at Week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade A or B from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Gread D: Mucosal breaks involving at least 75% of the esophageal circumference.

Time frame:
Baseline and Week 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Percentage of ParticipantsESO 40 mgRAB ER 50 mg
Yes87.888.2
No6.35.9
Missing5.95.9
PrimaryPercentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks

Healing at Week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade A or B from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present). Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Gread D: Mucosal breaks involving at least 75% of the esophageal circumference.

Time frame:
Baseline and Week 4
Reported as:
Number · Percentage of Participants
Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Percentage of ParticipantsESO 40 mgRAB ER 50 mg
Yes75.375.9
No2119.1
Missing3.75

Adverse events

Collected over For each participant, from the time of administration of the first dose of study drug up to 30 days after the administration of the last dose of study drug or up to resolution of adverse event or up to approximately 10 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ESO 40 mg—6/676 (0.9%)0/676 (0%)
RAB ER 50 mg—3/685 (0.4%)0/685 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventESO 40 mgRAB ER 50 mg
Acute myocardial infarctionCardiac disorders1/6760/685
GastroenteritisInfections and infestations1/6761/685
OsteoarthritisMusculoskeletal and connective tissue disorders1/6760/685
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6760/685
Neuroendocrine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6760/685
Rectosigmoid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6760/685
HeadacheNervous system disorders1/6760/685
AsthmaRespiratory, thoracic and mediastinal disorders1/6760/685
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/6760/685
Acute coronary syndromeCardiac disorders0/6761/685

Baseline characteristics

The analysis was performed using the Intent-to-Treat (ITT) population, defined as all randomized subjects who received at least 1 dose of study drug, minus two participants from one site who were excluded from the ITT Population per an agreement with the FDA due to concerns of possible misconduct.

Age, Continuous
Age, Continuous(Years)ESO 40 mgRAB ER 50 mgTotal
Mean46.6 ± 13.1647 ± 13.0246.8 ± 13.08
Sex: Female, Male
Sex: Female, Male(Participants)ESO 40 mgRAB ER 50 mgTotal
Female351379730
Male330318648
08

Study locations

85 sites
  • Huntsville, Alabama 35801, United States
  • Tucson, Arizona 85712, United States
  • Tucson, Arizona 85741, United States
  • Little Rock, Arkansas 72205, United States
  • Sherwood, Arkansas 72120, United States
  • Anaheim, California 92801, United States
  • Chula Vista, California 91910, United States
  • Fullerton, California 92835, United States
  • Irvine, California 92618, United States
  • Laguna Hills, California 92653, United States
  • Mission Hills, California 91345, United States
  • Redwood, California 94062, United States
  • San Diego, California 92123, United States
  • San Louis Obispo, California 93405, United States
  • West Covina, California 91790, United States
  • Pueblo, Colorado 81008, United States
  • Wheat Ridge, Colorado 80033, United States
  • Bristol, Connecticut 6010, United States
  • Hartford, Connecticut 6102, United States
  • Boynton Beach, Florida 33426, United States
  • Hialeah, Florida 33010, United States
  • Hollywood, Florida 33021, United States
  • Jacksonville, Florida 32256, United States
  • Jupiter, Florida 33458, United States
  • Largo, Florida 33777, United States
  • Lauderdale Lakes, Florida 33319, United States
  • Naples, Florida 34102, United States
  • Orlando, Florida 32806, United States
  • Tampa, Florida 33607, United States
  • Tampa, Florida 33613, United States
  • Tampa, Florida 33618, United States
  • Newnan, Georgia 30263, United States
  • Rockford, Illinois 61107, United States
  • Clive, Iowa 50325, United States
  • Kansas City, Kansas 66160, United States
  • Topeka, Kansas 66606, United States
  • Louisville, Kentucky 40202, United States
  • Louisville, Kentucky 40291, United States
  • Baton Rouge, Louisiana 70809, United States
  • Slidell, Louisiana 70458, United States
  • Annapolis, Maryland 21401, United States
  • Hagerstown, Maryland 21742, United States
  • Mexico, Missouri 65265, United States
  • Washington, Missouri 63090, United States
  • Vineland, New Jersey 8360, United States
  • Albuquerque, New Mexico 87106, United States
  • Bayshore, New York 11706, United States
  • Hartsdale, New York 10530, United States
  • Mineola, New York 11501, United States
  • New York, New York 10021, United States
  • Pittsford, New York 14534, United States
  • Boone, North Carolina 28607, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28209, United States
  • Jacksonville, North Carolina 28546, United States
  • New Bern, North Carolina 28562, United States
  • Wilmington, North Carolina 28401, United States
  • Fargo, North Dakota 58104, United States
  • Dayton, Ohio 45415, United States
  • Portland, Oregon 97210, United States
  • Portland, Oregon 97220, United States
  • Portland, Oregon 97225, United States
  • Anderson, South Carolina 29621, United States
  • Charleston, South Carolina 29414, United States
  • Columbia, South Carolina 29203, United States
  • Franklin, Tennessee 37067, United States
  • Germantown, Tennessee 38138, United States
  • Jackson, Tennessee 38301, United States
  • Johnson City, Tennessee 37604, United States
  • Kingsport, Tennessee 37660, United States
  • Nashville, Tennessee 37203, United States
  • Nashville, Tennessee 37211, United States
  • Beaumont, Texas 77701, United States
  • Bryan, Texas 77802, United States
  • Dallas, Texas 75231, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77079, United States
  • San Antonio, Texas 78229, United States
  • Chesapeake, Virginia 23320, United States
  • Bellevue, Washington 98004, United States
  • Spokane, Washington 92204-2318, United States
  • Spokane, Washington 99216, United States
  • Madison, Wisconsin 53715, United States
  • Milwaukee, Wisconsin 53209, United States
  • Milwaukee, Wisconsin 53215, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Apr 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2008
First posted
Apr 15, 2008
Start
Feb 2008
Primary completionActual
Apr 2009
CompletionActual
Sep 2009
Results first posted
Jun 23, 2015
Last update
May 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00658632
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Apr 15, 2008
Start date
Feb 2008
Primary completion
Apr 2009
Completion
Sep 2009
Results posted
Jun 23, 2015
Last update
May 4, 2016

Study contacts

Yufang Lu
study director · Eisai Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion